Abstract:Abstract Adoptive immunotherapy, in which tumor-reactive T cells are prepared in vitro for adoptive transfer to the patient, can induce an objective clinical response in specific types of cancer. In particular, chimeric antigen receptor (CAR)-redirected T-cell therapy has shown robust responses in hematologic malignancies. However, its efficacy against most of the other tumors is still insufficient, which remains an unmet medical need. Accumulating evidence suggests that modifying specific genes can enhance antitumor T-cell properties. Epigenetic factors have been particularly implicated in the remodeling of T-cell functions, including changes to dysfunctional states such as terminal differentiation and exhaustion. Genetic ablation of key epigenetic molecules prevents the dysfunctional reprogramming of T cells and preserves their functional properties. Clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas)-based gene editing is a valuable tool to enable efficient and specific gene editing in cultured T cells. A number of studies have already identified promising targets to improve the therapeutic efficacy of CAR-T cells using genome-wide or focused CRISPR screening. In this review, we will present recent representative findings on molecular insights into T-cell dysfunction and how genetic modification contributes to overcoming it. We will also discuss several technical advances to achieve efficient gene modification using the CRISPR and other novel platforms.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to improve the function of anti - tumor T cells through gene - editing technology in adoptive immunotherapy, especially in view of the still - insufficient treatment effect for most other tumors (non - hematological malignancies). Specifically, the paper explores the following aspects: 1. **T - cell Dysfunction**: The paper discusses that T cells may experience dysfunction under long - term antigen stimulation, such as terminal differentiation and exhaustion, and these states limit the persistence and effector function of T cells. 2. **Epigenetic Factors**: The paper emphasizes the important role of epigenetic factors in the remodeling of T - cell function, especially in preventing T - cell dysfunction and maintaining its functional characteristics. Through gene - editing technologies such as CRISPR/Cas9, key genes can be specifically knocked out or knocked in, thereby improving the treatment effect of CAR - T cells. 3. **CAR - T Cell Persistence**: The paper explores how to enhance the persistence of CAR - T cells through epigenetic modification, enabling them to remain active in the body for a long time and thus more effectively control tumors. 4. **T - cell Exhaustion**: The paper also discusses the problem of T - cell exhaustion, which is a state of decreased T - cell function due to long - term antigen stimulation. Through epigenetic modification, the occurrence of T - cell exhaustion can be reduced and the efficacy of CAR - T cells can be improved. 5. **Gene - editing Technologies**: The paper introduces the application of gene - editing technologies such as CRISPR/Cas9 in T cells and how to use these technologies to optimize the preparation and function of CAR - T cells. Overall, this paper aims to overcome the main obstacles in current CAR - T cell treatment through gene - editing technology, especially epigenetic modification, thereby improving its treatment effect in multiple tumor types.

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy

Genetically engineered T cells for cancer immunotherapy

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy

[Cancer Immunotherapy Using Gene Modification Technology]

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy

CRISPR–Cas9 applications in T cells and adoptive T cell therapies

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Gene modification strategies for next-generation CAR T cells against solid cancers

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

CRISPR-Cas9 Genome Editing for Cancer Immunotherapy: Opportunities and Challenges.

Building Potent Chimeric Antigen Receptor T Cells with CRISPR Genome Editing

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More